Gilead's Trodelvy Surpasses Investors' Low Bar At ASCO, But Faces A Commercial Climb
Executive Summary
The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.
You may also be interested in...
ESMO: Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again
The company is presenting overall survival data in HR+/HER2- breast cancer from the TROPiCS-02 at ESMO. Oncology clinical development head Bill Grossman talked with Scrip about how it differs from rival Enhertu.
Gilead’s Trodelvy Wins In TROPiCS-02, But Commercial Headwinds Remain
Analysts said that while the Phase III survival data could lead to Trodelvy’s FDA approval, it still could face competitive headwinds from AstraZeneca/Daiichi Sankyo’s Enhertu.
Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers
Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.